Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-08-19

Clinical Trial Update: Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Entresto (sacubitril/valsartan) to placebo in essential hypertension evaluated efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Entresto (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2015-08-19